SVCM
AVBP icon

Saturn V Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Saturn V Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-47,266
Closed -$1.11M – 29
2024
Q3 		$1.11M Buy
+47,266
New +$1.07M 0.4% 24

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Saturn V Capital Management's AVBP Position: Q4 2024 in Review

Saturn V Capital Management sold out of ArriVent BioPharma (AVBP) in Q4 2024, closing a stake of 47,266 shares — an estimated $1.11M sold.

Saturn V Capital Management first reported a position in AVBP in Q3 2024 and held it in 1 quarter. The position peaked at $1.11M in Q3 2024. 80 funds tracked by Wall St. Rank hold AVBP as of Q4 2024.

  • Saturn V Capital Management reported no remaining ArriVent BioPharma position as of Q4 2024 after selling out during the quarter.
  • Saturn V Capital Management sold 47,266 ArriVent BioPharma shares in Q4 2024, an estimated $1.11M.
  • Saturn V Capital Management first reported a position in ArriVent BioPharma in Q3 2024 and held it in 1 quarter.
  • Saturn V Capital Management's ArriVent BioPharma position peaked at $1.11M in Q3 2024.
  • 80 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q4 2024.

Based on Saturn V Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.